

Cumulative Index 1991

Volume 18

<i>March</i>	CHEMICAL DEPENDENCY AND PREGNANCY, pages 1-191
<i>June</i>	NEONATAL SEPSIS, pages 193-387
<i>September</i>	NEWER TECHNOLOGIES AND THE NEONATE, pages 389-651
<i>December</i>	HYPERTENSION AND PREGNANCY, pages 653-925

Note: Page numbers of issue and article titles are in **boldface** type.

- Abortion, spontaneous, and substance abuse, 28
- Acetylsalicylic acid. *See Aspirin.*
- Adolescents, pregnant, and substance use, **125-138**
 - background information, 127-130
 - current studies, 132-133
 - future directions, 133-138
 - family, health care, and environmental implications, 134-135
 - research implications, 135-136
 - past studies, 130-132
- Adrenoceptors, 686
- Air leaks, high-frequency ventilation treatment, 574
- Airway pressure measurement, 585
- Alcohol use in pregnancy, **93-111**
 - adverse effects, 100-101
 - alcohol related birth defects, 100-101
 - fetal alcohol syndrome, 100
 - breast feeding, 104
 - counseling and prenatal care, 104-106
 - genetic predisposition, 104-105
 - definitions, 93-94
 - alcohol abuse, 93
 - alcohol dependence, 94
 - alcoholic beverages, 94
 - drinking patterns, 98-99
 - economic implications, 104
 - incidence, 94
 - metabolism of aliphatic alcohols, 94-97
 - serum ethanol levels, intoxication symptoms, 96-97
 - recognition and assessment of abuse, 102-103
 - teratogenicity, 99-100
- Alcohols, aliphatic, metabolism of, 94-97
- Aldosterone, in normal pregnancy, 695 and renin release, 689. *See also Preeclampsia.*
- Amniotic fluid, foul smelling, and neonatal sepsis, 364
- Anemia in parvovirus B19 infection, 215-216
 - aplastic, 215
 - chronic, 215-216
- Anemometer, hot wire, 584-585
- Anesthesia, for preeclampsia, **875-889**
 - in labor and delivery, 885-886
 - epidural, 886
 - parenteral narcotics, 885
 - management, 878-885
 - epidural anesthesia, 880-881
 - general anesthesia, 881-885
 - labetalol, 884-885
 - nitroglycerine, 884
 - nitroprusside, 883-884
 - trimethaphan, 884
 - monitoring, 879-880
 - preoperative preparation, 878-879
 - and pulse oximetry, 464-465
- Angiography, cerebral pathology in eclampsia, 901-902
- Angiotensin. *See Preeclampsia.*
- Angiotensin II, in normal pregnancy, 693 in preeclampsia, 699 and renin release, 687-689

- Angiotensin II (*Continued*)
 sensitivity, 693-695, 699-700
 Angiotensin converting enzyme, inhibitors, 853
 in normal pregnancy, 693
 in preeclampsia, 698-699
 and renin release, 687
 Angiotensinogen, in normal pregnancy, 692-693
 and renin release, 687
 Animal models, using magnetic resonance spectroscopy, 545
 of opiate, cocaine, and cannabis use, 1-22
 cannabis and delta-9-tetrahydrocannabinol, 12-18
 brain DNA, RNA, and protein, 17
 chemistry, 13-15
 delta-9-tetrahydrocannabinol, 15
 plasma levels, 18
 maternal nutrition and embryotoxicity, 15-16
 offspring, behavior, 16-17
 growth, 16
 cocaine, 8-12
 maternal-fetal physiology, 9-10
 neurobehavioral effects, 10-12
 neurotoxicity, 10
 opiates, 2-8
 methadone studies, 2-5
 neonatal withdrawal, 5-8
 Antibodies, congenital and acquired
 deficiency, immunoglobulin therapy, 311
 in HIV infection, 37-38, 230
 Antigens, bacterial, and neonatal sepsis, 368-369
 HIV, 37
 P24, in HIV infection, 229
 Antihypertensive drugs, Doppler flow velocimetry, 766-769
 maternal, fetal assessment, 824-825
 in preeclampsia, 796-799
 in pregnancy, 841. *See also Hypertension and pregnancy.*
 Antithrombin III, 714-716
 Apnea, obstructive, 477-478
 Artificial skin. *See Thermoregulation.*
 Asphyxia, perinatal, and neonatal sepsis, 364
 PET measurements, cerebral blood flow, 556-557
 deoxyglucose uptake, 557
 Aspirin, and preeclampsia, 657-658, 787-788
 Auditory system. *See Evoked potential assessment of auditory system.*
 Baroreceptor, intrarenal, 685
 Behavior, cannabis effects, 16-17
 Biomedical technology, 389-401
 guidelines, 398-400
 intelligent use, 398-399
 research, 399-400
 self-restraint, 399
 risks and pitfalls, 397-398
 use of, 391-397
 to alleviate work load of caretakers, 394-395
 to impress other physicians, patients, and visitors, 397
 to improve care and diagnostic ability, 391-393
 to improve documentation, 395-396
 and medical liability, 396-397
 Biophysical testing, antepartum fetal, 820
 Birth defects, alcohol related, 101, 104
 and substance abuse, 27
 Blood culture, for neonatal sepsis, 366
 Blood flow, cerebral. *See Positron emission tomography.*
 fetal and placental, Doppler flow velocimetry, 750-751
 Blood pressure, in hypertension and pregnancy, 846-847
 in preeclampsia, 728-730
 in pregnancy, 654-655
 Blood volume in preeclampsia, 727-728
 Body, electrical conductivity. *See Electrical conductivity, total body.*
 hoods. *See Thermoregulation.*
 weight and growth, and pulmonary function, 605
 Brain, DNA, RNA, and protein, cannabis effects, 17
 magnetic resonance spectrum, 537-540
 Brainstem, auditory response, 500-506
 Breast feeding, and alcohol use, 104
 and cocaine use, legal issues, 164-165
 and substance abuse, 70
 Bronchopulmonary dysplasia, and mycoplasma infections, 245-248
 Bunnell Life Pulse, 564-566
 C-reactive protein, and neonatal sepsis, 372-373
 Calcium, and preeclampsia, 658
 Calcium channel blockers, for hypertension in pregnancy, 853
 Candidiasis, neonatal, 263-280
 congenital, 265-267
 diagnosis, 272-273
 postnatal colonization, 267-268
 postnatal mucocutaneous infection, 268-269
 predisposing factors, 264-265
 systemic, in low birthweight infants, 269-272

- cardiovascular, 270
- central nervous system, 270
- cutaneous, 272
- endophthalmitis, 270-271
- gastrointestinal, 271
- osteoarthritis, 272
- pulmonary, 269-270
- urinary tract, 271
- in term infants, 272
- treatment, 273-275
- Cannabis, animal models of use, 12-18
 - See also *Marijuana use in pregnancy.*
- Capillary wedge pressure, pulmonary, 733
- Cardiac output, antihypertensive drugs, 850-851
 - in preeclampsia, 730-732
- Cardiomyopathy, in HIV infection, 232-233
- Cardiorespiratory monitoring, 473-495
 - apnea, obstructive, 477-478
 - blood gases, 476-477
 - documented monitoring, 483-494
 - heart rate, 475-476
 - pneumograms, 478-483
 - clinical usefulness, 479-483
 - performance and analysis standards, 478-479
 - respiration, 474-475
- Cardiovascular system, aspirin effects, 788
- candidiasis, 270
 - of pregnant substance abuser, 26.
- Central nervous system, candidiasis, 270
- mycoplasma infections, 249-252
- Cerebral, blood flow, and neuronal viability and neurologic outcome, 558
 - in perinatal asphyxia, 556-557
 - PET measurements, intraventricular hemorrhage, 555-556
 - hypoxia-ischemia, 540-542
 - oxygen metabolism, PET measurements, 559
 - ultrasonography, and magnetic resonance spectroscopy, 543-545
- Cerebrospinal fluid, in eclampsia, 895-896
- in neonatal sepsis, 366-367
- Child dependency and pregnancy, 1-186
 - adolescent substance use, 125-138
 - background information, 127-130
 - current studies, 132-133
 - future directions, 134-136
 - past studies, 130-132
 - alcohol use, 93-111
 - adverse effects, 100-101
 - breast feeding, 104
 - counseling and prenatal care, 104-106
 - definitions, 93-94
 - fetal alcohol syndrome, 100-101
 - incidence, 94
 - metabolism of aliphatic alcohols, 94-97
 - in pregnancy, 97-99
 - recognition and assessment of abuse, 102-103
 - teratogenicity, 99-100
 - animal models of opiate, cocaine, and cannabis use, 1-22
 - cannabis and delta-9-tetrahydrocannabinol, 12-18
 - cocaine, 8-12
 - opiates, 2-8
 - cocaine use, 113-123
 - and developmental defects, 139-146
 - background data, 139-141
 - prenatal effects, 141-144
 - methodologic issues, 117-120
 - pharmacology and clinical outcome, 120-121
 - review of current studies, 113-117
 - drug use in pregnancy, 23-32
 - detection, 25
 - management, 26-30
 - prevalence, 24-25
 - HIV infection, 33-50
 - and course of HIV infection, 42-43
 - detection of, 36-39
 - epidemiology, 35
 - life cycle of HIV virus, 33-34
 - management, 43-46
 - perinatal issues, 39
 - and pregnancy outcome, 41-42
 - risk of perinatal transmission, 39-41
 - transmission modes, 35-36
 - legal issues, 147-186
 - historical background, 148-164
 - state intervention, 164-183
 - marijuana use, 77-91
 - epidemiology, 77-80
 - infant outcome, 83-86
 - long-term effects on offspring, 86-87
 - methodologic issues, 80-83
 - narcotic use, 51-76
 - breast feeding, 70
 - cofactors and complications, 56-57
 - diagnosis, 57-60
 - management, 62-67
 - intrapartum, 68-69
 - postpartum, 71-72
 - neonatal abstinence syndrome, 68-70
 - neonatal withdrawal and infant outcome, 71
 - opioids, disposition and pharmacology, 53-54
 - uses in pregnancy, 67-68
 - teratogenicity, 54-56
 - work-up of pregnant addict, 60-62
 - Chemotherapy for herpes simplex virus infection, 202-204
 - Child abuse law, 154-159
 - Childbirth. See *Legal issues, drug addiction and pregnancy.*

- Children, long-term effects of prenatal marijuana exposure, 87
- Chorioamnionitis, 362-363
- Chromatography, high performance liquid, 635
- thin layer, 632-634
- Civil intervention during pregnancy, 181-182
- Classification, chronic hypertension in pregnancy, 833
- coagulase-negative staphylococci, 282-283
- Clinicopathology of diagnosis of neonatal sepsis, 361-381
- diagnostic tests, nonspecific, 369-375
- acute phase reactants, 373
- C-reactive protein, 372-373
- erythrocyte sedimentation rate, 373
- miscellaneous tests, 373-374
- screening tests, 375
- white blood cell count, 369-372
- laboratory tests, specific, 365-369
- bacterial antigens, 368-369
- blood culture, 366
- cerebrospinal examination and culture, 366-367
- tracheal aspiration, 368
- urine culture, 367-368
- management, 375-377
- asymptomatic neonate, 375-377
- symptomatic neonate, 375
- risk factors, 362-365
- additive risks and screening scores, 364
- amniotic fluid smell, 364
- asphyxia, perinatal, 364
- male gender, 364
- maternal colonization with group B streptococcus, 363
- maternal urinary tract infection, 364
- prematurity, 363-364
- prolonged rupture of membranes and chorioamnionitis, 362-363
- Coagulation, aspirin effects, 789. See also *Preeclampsia*.
- Cocaine, in pregnancy, 113-123
- animal models of use, 8-12
- and breast feeding, legal issues, 164-165
- and developmental defects, 139-146
- background data, 139-141
- prenatal effects, 141-144
- methodologic issues, 117-120
- comparison groups, 120
- environment, 119-120
- pattern of use and dose, 118-119
- polydrug use, 117
- site of study, 118
- timing, 117-118
- pharmacology of, and clinical outcome, 120-121
- review of current studies, 113-117
- Colloid oncotic pressure, 735-737
- Color or spot test, in prenatal drug exposure, 632
- Compliance. See *Pulmonary function, measurement and monitoring*.
- Computerized tomography, cerebral pathology in eclampsia, 898-901
- Conductive impairment, and auditory brainstem response, 505
- Confidentiality, maternal, 152
- child abuse law, 156-157
- Constitutional law. See *Legal issues, drug addiction and pregnancy*.
- Corneal ulceration, fibronectin therapy, 328-330
- Cortical auditory evoked potentials, 507-509
- Counseling, alcohol use in pregnancy, 105-106
- for HIV infection, 236
- Covariates of marijuana use during pregnancy, 83
- Criminalization. See *Legal issues, drug addiction and pregnancy*.
- Cruel and unusual punishment, 154
- Cutaneous candidiasis, 272
- Cytokine therapy, 343-359
- granulocyte-colony stimulating factor, 348-349
- granulocyte-monocyte colony stimulating factor, 347-348
- hematopoiesis, 346-347
- hematopoietic colony stimulating factors, 345-346
- interleukin-3, 349-350
- myeloid abnormalities, 344-345
- myeloid progenitor deficiency, 344
- neutrophil storage pools, 344-345
- neutrophil physiological function, 345
- and neonatal host defense, 351-355
- mature cell effector function, 353
- myeloid proliferation and kinetics, 351-353
- sepsis modulation, 354-355
- other cytokines, 350-351
- Data interpretation, in near-infrared spectroscopy, 525-527
- respiratory mechanics measurements, 604-606
- Delivery room, HIV infection, 234
- pulse oximetry in, 463-464
- Delta-9-tetrahydrocannabinol, animal models of use, 12-18
- Deoxyglucose uptake, in perinatal asphyxia, 557
- Development, aspirin effects, 789
- cerebral glucose metabolism, 558
- fetal vascular disruption, cocaine effects, 139-146

- Diazoxide, for hypertension in pregnancy, 852
- Diuretics, for hypertension in pregnancy, 854
- DNA, brain, cannabis effects, 17
- Documentation, and biomedical technology, 395-396
- cardiorespiratory monitoring, 483-494
- Doppler flow velocimetry, 749-778
- antepartum fetal, 821-824
- blood flow, fetal and placental, 750-751
- during drug therapy, 764-772
- antihypertensive therapy, 766-769
- labetalol, 764-766
- nifedipine, 764-766
- in preeclampsia, 769-772
- and maternal and fetal well being, 756-757
- and other fetal monitoring tests, 757-763
- safety of, 772
- as screening test, 755-756
- spectrum analysis, 751-752
- waveforms, 751
- fetal and uteroplacental, 753-754
- pathophysiology of abnormalities, 754-755
- shaping factors, 752-753
- Drugs, in pregnancy, 23-32
- detection, 25
- management, 26-30
- chemical dependency, 29-30
- health education, 30
- labor management, 30
- maternal complications, 26-27
- obstetrical complications, 27-29
- social services, 30
- prevalence, 24-25
- prenatal exposure, 629-645
- laboratory tests, 631-636
- gas chromatography, 635
- and mass spectrometry, 636
- high performance liquid chromatography, 635
- immunoassay, 634-635
- thin layer chromatography, 632-634
- maternal interview, 630-631
- specimens used, 636-643
- hair, 641-643
- meconium, 637-641
- other fluids and tissues, 643
- urine, 636-637
- cerebrospinal fluid pressure monitoring, 895-896
- computerized tomography, 898-901
- electroencephalogram, 896-898
- magnetic resonance imaging, 901
- pathology, 895
- pathophysiology, 893-894
- visual manifestations, 902. See also *Preeclampsia*.
- Ecology, of coagulase-negative staphylococcal infection, 284-285
- Edema, pulmonary, 737-740
- Electrical conductivity, total body, 611-627
- applications, 622-624
- data interpretation, 617-621
- biologic meaning, 617-618
- fat-free mass, 618-621
- future developments, 624-625
- instrumentation, 615-616
- measurement precision and accuracy, 621-622
- tissue properties and measurement theory, 612-615
- Electroencephalogram, cerebral pathology in eclampsia, 896-898
- Electrolytes, and renin release, 686
- Electrophysiology of auditory system evaluation, 498-499
- ELISA, of HIV infection, 230
- Embryopathy, in HIV infection, 232
- Endocarditis, in coagulase-negative staphylococcal infection, 289
- Endophthalmitis, 270-271
- Endothelium in preeclampsia, 669-671
- Enterocolitis, necrotizing, 290
- Environment, and cocaine use, 119-120
- and pregnant adolescents, 134-135
- Epidemiology, of coagulase-negative staphylococcal infection, 283-284
- of HIV infection, 35, 227
- of marijuana use during pregnancy, 77-80
- of mycoplasmal infections, 242-243
- of parvovirus B19, human, 212
- Epidural anesthesia, 880-881, 886
- Equal protection, legal issues, 153-154
- Erythema infectiosum, 213-214
- Erythrocyte sedimentation rate, and neonatal sepsis, 373
- Esophagus, pressure measurements, 585-587
- Ethanol serum levels, 96-97
- Etiology of chronic hypertension in pregnancy, 833
- Evoked potential assessment of auditory system, 497-518
- auditory brainstem response, 500-506
- automatic screening, 505-506
- and conductive impairment, 505
- test stimuli, 504
- when to test, 502-503
- Eclampsia, cerebral pathology, 891-910
- diagnosis and clinical features, 891-892
- management, 902-907
- neurodiagnostic evaluation, 895-902
- angiography, 901-902

- Evoked potential assessment of auditory system (*Continued*)
 where to test, 503-504
 case studies, 509-516
 brainstem response threshold elevation with near-normal hearing, 511-514
 normal ABR with cortical dysfunction, 514-516
 transient threshold elevation, 509-511
 unilateral hearing loss status post meningitis, 511
 cortical auditory evoked potentials, 507-509
 electrophysiologic techniques, 498-499
 middle latency responses, 506
 Exhalation, passive, 594-595
- Factor VIII, in preeclampsia, 716-717
 False-positive antibody tests, in HIV infection, 231
 Family of pregnant adolescents, 134-135
 Fat-free mass, from total body electrical conductivity, 618-621
 FDA status of high-frequency ventilators, 564-568
 Fetal alcohol syndrome, definition, 100
 economic implications, 104
 incidence, 100
 Fetus, alcohol effects, 96-97
 antepartum assessment, 809-832
 assessment methods in hypertensive pregnancies, 825-827
 biophysical testing, 820
 Doppler velocimetry of vascular system, 821-824
 fetal-placental pathophysiology in hypertension, 810-813
 heart rate testing, 814-820
 maternal antihypertensive agents, 824-825
 obstetric ultrasound, 813-814
 blood flow. *See Doppler flow velocimetry.*
 and chronic hypertension in pregnancy, 835
 coagulation, preeclampsia effects, 720
 cocaine effects, 9-10, 139-146
 legal issues. *See Legal issues, drug addiction and pregnancy.*
 parvovirus B19 infection, 217-219
 of pregnant substance abuser, 28-29
 risks of hypertension, 849-850
 Fibrin metabolism, 717-718
 Fibrinectin therapy, 325-341
 clinical trials, 328-334
 in corneal ulceration, 328-330
 in multisystem organ failure, 330-334
 immunotherapy in newborn infants, 335-338
 structure-function relationships, 326-328
 Fifth disease, 213-214
 Functional residual capacity, 602-604
- Gas chromatography, of prenatal drug exposure, 635
 and mass spectrometry, 636
 Gas exchange, in high-frequency ventilators, 568-573
 Gases, blood, in cardiorespiratory monitoring, 476-477
 Gastrointestinal candidiasis, 271
 Gastrointestinal system of pregnant substance abuser, 27
 Genetics of alcoholism, 104-105
 Gestation length, marijuana effects, 85
 Glasgow Royal Maternity Hospital protocol, 862-866
 Glucose metabolism, cerebral, developmental changes, 558
 Granulocyte-colony stimulating factor, 348-349
 Granulocyte-monocyte colony stimulating factor, 347-348
 Green light, for neonatal jaundice, 427-428
 Growth, cannabis effects, 16
 intrauterine, marijuana effects, 83-85
 retardation, and substance abuse, 28-29
- Hair, in prenatal drug exposure, 641-643
 Halogen lamp (metal halide lamp), for neonatal jaundice, 428-429
 Health education for pregnancy substance abuser, 30
 Heart rate, in cardiorespiratory monitoring, 475-476
 fetal, 814-820
 HELLP syndrome in preeclampsia, 803-805
 Hematology, in parvovirus B19 infection, 215-216
 Hematopoiesis, 346-347
 Hematopoietic colony stimulating factors, 345-346
 Hemodynamics of preeclampsia. *See Preeclampsia.*
 Hemorrhage, intraventricular, PET measurements, 555-556
 Hepatosplenomegaly, in HIV infection, 233
 Herpes simplex virus infection, neonatal, 193-208
 antenatal screening programs, 193-196
 chemotherapy, 202-204
 determinants of disease acquisition and severity, 199-202
 recognition and diagnosis of, 196-199
 HFV Infant Star ventilator, 567

- Homicide, of unborn fetus, 163-164
- Host factors, in coagulase-negative staphylococcal infection, 285-286
- Human immunodeficiency virus (HIV) infection, 227-239
- clinical manifestations, 232-233
 - cardiomyopathy, 232-233
 - embryopathy, 232
 - hepatosplenomegaly, 233
 - lymphadenopathy, 233
 - opportunistic, 232
 - pulmonary disease, 233
 - recurrent or persistent infection, 233
 - sexually transmitted, 232
 - thrush, 233
 - toxicology, 232
 - counseling, 236
 - epidemiology, 227
 - laboratory diagnosis, 228-232
 - HIV antibodies, 230
 - clonally distinct antibodies, 230
 - ELISA, 230
 - Western Blot, 230
 - HIV assays, 228-230
 - lymphocyte p24-FCA, 230
 - P24 antigen, 229
 - polymerase chain reaction, 229
 - viral culture, 228-229
 - immunoglobulin antibodies, 230-232
 - false-positive antibody tests, 231-232
 - IgA, 231
 - IgG subclass, 230
 - IgM, 230-231
 - lymphocyte subclasses, 231
 - neopterin, 232
 - in vitro antibody synthesis, 231
 - management, 236
 - postnatal acquisition, 233-234
 - cross infection, 234
 - in delivery room, 234
 - milk, 233
 - needles, 234
 - transfusion, 234
 - in pregnancy, 33-50
 - and course of HIV infection, 42-43
 - detection, 36-39
 - antibodies, 37-38
 - antigens, 37
 - polymerase chain reaction, 38-39
 - viral culture, 38
 - epidemiology, 35
 - life cycle of HIV, 33-34
 - management, 43-46
 - antepartum, 44-45
 - intrapartum, 45
 - postpartum, 46
 - perinatal issues, 39
 - and pregnancy outcome, 41-42
 - transmission, 35-36
 - perinatal, 39-41
 - screening policy, 235-236
 - transmission, 228
 - treatment, 234-235
 - agents, 235
 - whom to treat, 234-235
- Humming II ventilators, 566-567
- Hydralazine, 852
- Hypertension and pregnancy, 653-910
- chronic, 833-844
 - antihypertensive drugs, 841
 - control of, 836
 - diagnosis, 833-834
 - etiology and classification, 833
 - management, 841-843
 - maternal and fetal risks, 835
 - mild hypertension, 837-840
 - severe hypertension, 836-837
 - Doppler flow velocimetry, 749-778
 - blood flow, fetal and placental, 750-751
 - during drug therapy, 764-772
 - and maternal and fetal well being, 756-757
 - and other fetal monitoring tests, 757-763
 - pathophysiology of abnormalities, 754-755
 - safety of, 772
 - as screening technique, 755-756
 - spectrum analysis, 751-752
 - waveform, 751
 - physiologic changes, 753-754
 - shaping factors, 752-753
 - eclampsia. *See Eclampsia, cerebral pathology.*
 - fetus, antepartum assessment, 809-832
 - assessment methods, 825-827
 - Doppler velocimetry of maternal and fetal vascular systems, 821-824
 - fetal heart rate testing, 814-820
 - fetal-placental pathophysiology, 810-813
 - maternal antihypertensive agents, 824-825
 - multiple parameter biophysical testing, 820
 - obstetric ultrasound, 813-814
 - hypertensive drugs, 845-873
 - angiotensin converting enzyme inhibitors, 853
 - beneficial effects, 854-862
 - chronic hypertension, 855-856
 - mild to moderate hypertension, 859-860
 - one therapy, two patients, 855
 - preeclampsia, 856-857
 - severe hypertension, 857-859
 - cardiac output alterations, 850-851
 - labetalol, 851
 - centrally acting, 850
 - methyldopa, 850

- Hypertension and pregnancy (*Continued*)
 definition, 845-848
 blood pressure levels, 846
 blood pressure measurements, 846-847
 causes, 848
 diagnosis, 847-848
 types of hypertension, 845-846
 diuretics, 854
 fetal-placental side effects, 861
 Glasgow Royal Maternity Hospital protocol, 862-866
 before twenty weeks or chronic hypertension, 862-864
 delivery, 865
 hypertensive crisis, 864-865
 postdelivery, 865
 after twenty weeks, 864
 metabolism of drugs, 860-861
 other effects, 861-862
 peripheral vascular resistance, 851-853
 calcium channel blockers, 853
 diazoxide, 852
 hydralazine, 852
 nitroprusside, 852
 potential harm, 848-850
 fetal risks, 849-850
 maternal risks, 848-849
 new concepts, 653-659
 blood pressure, 654-655
 diagnosis, 654
 etiology, 656
 future, 658-659
 prevention, 657-658
 uteroplacental bed, 656-657
 who is sick? 655-656. See also *Pre-eclampsia*.
 Hypoxia-ischemia, cerebral, 540-542
 prediction of outcome, 541-542
 time course of changes, 540-541
- Imaging, magnetic resonance, 536
 Immunity, child abuse law, 157
 Immunoassay, of prenatal drug exposure, 634-635
 Immunocompromised patients, parvovirus B19 infection, 215-216
 Immunoglobulins, in HIV infection, 230-232
 IgA, 231
 IgG, 230
 IgM, 230-231
 prophylaxis and therapy, 303-323
 in congenital and acquired antibody deficiency, 311
 intravenous utilization, 305-308, 314-320
 adverse effects, 318-320
 infection prophylaxis protocols, 314-315
 therapy for sepsis, 315-318
 pharmacokinetics, 312-314
 risk factors, 308-311
 Incubators. See *Thermoregulation*.
 Infants, candidiasis, and low birthweight, 269-272
 in term infants, 272
 newborn, fibronectin therapy, 335-338
 pneumonia, and mycoplasmal infections, 248
 and prenatal marijuana use, 83-86
 Infectious disease, in pregnant substance abuser, 26-27, 67. See also *Sepsis, neonatal*.
 Informed consent, and neonatal drug dependency, 169-170
 Instrumentation, for near-infrared spectroscopy, 522-525
 in pulse oximetry, 454-455
 for total body electrical conductivity, 615-616
 Interleukin-3, 349-350
 Intoxication symptoms, 98-99
- Jaundice, neonatal. See *Phototherapy for neonatal jaundice*.
 Joint disease, parvovirus B19 infection, 214-215
- Kinetics, myeloid proliferation, 351-353
- Labetalol, and Doppler flow velocimetry, 764-766
 for hypertension in pregnancy, 851
 in preeclampsia, 884-885
 Labor and delivery, anesthesia for, 885-886
 inhibition by aspirin, 789
 and substance abuse, 28, 30
 Lamps for phototherapy, 432-434
 green light, 427-428
 halogen, 428-429
 Legal issues, drug addiction and pregnancy, 147-166
 conclusions, 178-183
 civil intervention during pregnancy, 181-182
 criminalization of prenatal conduct, 178-181
 mandatory reporting of neonatal addiction, 182-183
 removal of drug-dependent infants, 183
 historical background, 148-164

- child abuse law, 154-159
 - duty to report, common law, 158-159
 - statutory, 155-157
 - failure to report, 157-158
- constitutional law, 148-154
 - cruel and unusual punishment, 154
 - equal protection, 153-154
 - fetus under 14th amendment, 148-150
 - maternal privacy rights, 150-152
 - autonomy rights, 151-152
 - bodily integrity, 150-151
 - confidentiality, 152
 - parental authority, 152-153
 - religious exercise, 154
- tort and criminal law, 159-164
 - fetus in USC 1983, 163
 - homicide, 163-164
 - preconception torts, 162-163
 - prenatal tort vs. mother, 161-162
 - third party and prenatal injury, 159-161
 - alive child, 159-160
 - wrongful death, 160-161
- state intervention, 164-183
 - cocaine intoxication through breast feeding, 164-165
 - court-ordered treatment, 172-174
 - criminalization, 175-178
 - arguments in favor of, 177-178
 - existing statutes and case law, 175-177
 - neonatal drug dependency, 165-170
 - case law, 165-167
 - informed consent, 169-170
 - state statutes, 167-169
 - prenatal drug use, 170-175
 - court-ordered treatment, 172-174
 - fetus not a child, 170-172
 - Minnesota statute, 174-175
- Liability, medical, and biomedical technology, 396-397
- Life cycle of human immunodeficiency virus, 33-34
- Lung disease, chronic, of newborn, and mycoplasmal infections, 245-248
 - and respiratory failure, high-frequency ventilation, 574-576
- Lung inflation, during high-frequency ventilation, 571-573. See also *Pulmonary function, measurement and monitoring*.
- Lymphadenopathy, in HIV infection, 233
- Lymphocyte p24-FCA, 230
- Lymphocytes, subclasses in HIV infection, 231
- Magnetic resonance imaging, cerebral pathology in eclampsia, 901
- Male gender, and neonatal sepsis, 364
- Marijuana use in pregnancy, 77-91
 - epidemiology, 77-80
 - patterns of use, 78-79
 - prenatal use, 79-80
 - prevalence in women of childbearing age, 77-78
 - rates of use during pregnancy, 78
 - infant outcome, 83-86
 - gestation length, 85
 - intrauterine growth, 83-85
 - morphological abnormalities, 85-86
 - neurobehavioral characteristics, 86, 87
 - offspring growth at follow-up, 86
 - prenatal exposure and subsequent development, 87
 - methodology, 80-83
 - assessment methods, 80-82
 - covariate selection, 83
 - timing of assessment, 82-83
- Maternal, complications with drug use, 26-27
 - cardiovascular, 26
 - gastrointestinal, 27
 - infectious disease, 26-27
 - neurologic, 26
 - nutrition, 27
 - respiratory, 27
- drug exposure, 630-631
- and fetal physiology, cocaine effects, 9-10
- legal issues. See *Legal issues, drug addiction and pregnancy*.
- nutrition and embryotoxicity, cannabis effects, 15-16
- opioid addiction, postpartum management, 71-72
- parvovirus B19 infection, 216-217
- prenatal tort action, 164-165
- streptococcal infection, and neonatal sepsis, 363
- urinary tract infection, 364
- Mathematical models of PET, cerebral, 552-554
 - blood flow, 553
 - blood volume, 553-554
 - glucose metabolism, 554
 - oxygen metabolism, 554
- Meconium, in prenatal drug exposure, 637-641
- Membranes, prolonged rupture of, and neonatal sepsis, 362-363
- Meningitis, in coagulase-negative staphylococcal infection, 289-290
 - and unilateral hearing loss, 511
- Metabolic studies, using magnetic resonance spectroscopy, 542-543
- Methadone maintenance, animal models, 2-5

- Methadone maintenance (*Continued*)
 of pregnant substance abusers, 65-66
- Methodology, assessment of marijuana use during pregnancy, 80-83
- Methyldopa for hypertension in pregnancy, 850
- Middle latency responses, in neonates and infants, 506
- Midtrimester severe preeclampsia, 801-803
- Milk, and HIV infection, 233
- Minnesota legislation, pregnancy intervention, 174-175
- Monitoring of fetus, Doppler flow velocimetry, 757-763
- Morphological abnormalities, and prenatal marijuana, 85-86
- Mucocutaneous infection, in candidiasis, 268-269
- Mycoplasmal infections, 241-262
 central nervous system infections, 249-252
 chronic lung disease of newborn, 245-248
 diagnosis and treatment, 256-259
 epidemiology, 242-243
 genital mycoplasmas, 254
 neonatal sepsis, 253-254
 pathology, 254-256
 pneumonia during infancy, 248
 respiratory disease, 243-245
 congenital and neonatal pneumonia, 243-245
- Myeloid, neonatal, abnormalities, 344-345
 proliferation and kinetics, 351-353
- Narcotic use in pregnancy, 51-76
 appropriate uses, 67-68
 breast feeding, 70
 cofactors and complications, 56-57
 diagnosis, 57-60
 disposition and pharmacology, 53-54
 management, 62-67
 abstinent addict in recovery, 66
 infection surveillance, 67-68
 intrapartum, 68
 methadone maintenance, 65-66
 opioid withdrawal, 62-65
 other therapeutic agents, 67
 postpartum, 71-72
 relapse, 66-67
 substance abuse treatment, 67
 neonatal abstinence syndrome, 68-70
 neonatal withdrawal and infant outcome, 71
 parenteral, 885-886
 teratogenicity, 54-56
 work-up of pregnancy addict, 60-62
- Near-infrared spectroscopy. *See Spectroscopy, near-infrared.*
- Needles, and HIV infection, 234
- Neonates, abstinence syndrome, 68-70
 drug dependency, legal issues. *See Legal issues.*
 opiate effects, animal models of withdrawal, 5-8
 subacute withdrawal, 71
- Neopterin, in HIV infection, 232
- Nerves, adrenergic, of uteroplacental bed, 656
- Neurobehavioral effects, cocaine effects, 10-12
 opiates, in neonates, 5-8
 prenatal marijuana effects, children, 87
 newborn, 86
- Neurology, and cerebral blood flow and neuronal viability, 558
 of pregnant substance abuser, 26
- Neurotoxicity, animal models of cocaine use, 10
- Neutrophils, physiological function, 345
 storage pools, 344-345
- Nifedipine, and Doppler flow velocimetry, 764-766
 in preeclampsia, 769-772
- Nitroglycerine, in preeclampsia, 884
- Nitroprusside, for hypertension in pregnancy, 852
 in preeclampsia, 883-884
- Nursing, and pulse oximetry, 462-463
- Nutrition, in preeclampsia prevention, 780-785
 of pregnant substance abuser, 27
- Obstetrics, and substance abuse, 27-29
 abortion, 29
 birth defects, 27
 fetal distress, 29
 intrauterine growth retardation, 28-29
 preterm labor, 28
 spontaneous abortion, 28
 stillbirth, 29
- Occlusion method, of pulmonary function measurement, 591-595
- Oliguria, in preeclampsia, 740-741
- Opiates, animal models of use, 2-8
 pharmacology, 53-54. *See also Narcotic use in pregnancy.*
- Organ failure, multisystem, fibronectin therapy, 330-334
- Osteoarthritis, and candidiasis, 272
- Oxygen metabolism, cerebral, PET measurement, 559
- Oxygenation during high-frequency ventilation, 570-571. *See also Pulse oximetry.*

- P24 antigen, 229
- Parental authority, 152-153
- Parvovirus B19, human, 209-225
- epidemiology and natural history, 212
 - erythema infectiosum (fifth disease) and other rash diseases, 213-214
 - future needs, 220-221
 - hematologic complications, 215-216
 - aplastic anemia with increased red blood cell turnover, 215
 - chronic anemia in immunocompromised patients, 215-216
 - joint disease, 214-215
 - laboratory diagnosis, 219-220
 - in pregnancy, 216-219
 - fetal and neonatal infections, 217-219
 - maternal, 216-217
 - virologic background, 210-212
- Pharmacokinetics of intravenous immunoglobulin, 312-314
- Pharmacology, of cocaine, 120-121
- opiod, in pregnancy, 54
- Photon attenuation, in PET, 551-552
- Phototherapy for neonatal jaundice, 432-439
- efficacy of, 424-427
 - green light, 427-428
 - halogen lamp, 428-429
 - indications for, 430-431
 - infant well-being during, 434-437
 - lamp efficacy, 432-434
 - mechanism of action, 429
 - termination of, 431-432
- Placenta, abruptio, and substance abuse, 29
- antihypertensive drug effects, 861
 - pathophysiology in hypertension, 810-813
- Plant chemistry, of cannabis, 13
- Plasma volume expansion, 742-745
- Platelets, in preeclampsia, 718-720
- Pneumograms, in cardiorespiratory monitoring, 478-483
- Pneumonia, in coagulase-negative staphylococcal infection, 290-291
- in mycoplasmal infections, congenital and neonatal, 243-245
 - during infancy, 248
- Pneumotachometer, 582-585
- Polymerase chain reaction, HIV detection, 38-39, 229
- Positron emission tomography, 549-562
- principles of, 549-554
 - mathematical models, 552-554
 - photon attenuation, 551-552
 - radiotracers, 552
 - spatial resolution, 551
 - studies in infants, 555-559
 - cerebral blood flow, in intraventricular hemorrhage, 555-556
 - neuronal viability, and neurologic outcome, 558
 - in perinatal asphyxia, 556-557
- cerebral oxygen metabolism, 559
- deoxyglucose uptake, in perinatal asphyxia, 557
- developmental changes in cerebral glucose metabolism, 558
- Preconception torts, 162-163
- Preeclampsia, anesthesia, 875-889
- for labor and delivery, 885-886
 - management, 878-885
 - epidural anesthesia, 880-881
 - general anesthesia, 881-885
 - monitoring, 879-880
 - preoperative preparation, 878-879
- antihypertensive drugs, 856-857
- eclampsia and coagulation, 713-726
- antithrombin III and thrombin antithrombin complexes, 714-716
 - coagulation abnormalities, 721-722
 - factor VIII, 716-717
 - and fetal coagulation, 720
 - fibrin metabolism, 717-718
 - other soluble factors, 717
 - platelets, 718-720
 - proteins C and S, 716
- hemodynamics, 727-747
- blood pressure, 728-730
 - blood volume, 727-728
 - cardiac output, 730-732
 - colloid oncotic pressure, 735-737
 - oliguria, 740-741
 - plasma volume expansion, 742-745
 - pulmonary capillary wedge pressure, 733
 - pulmonary edema, 737-740
 - systemic vascular resistance, 732
- management, 793-808
- HELLP syndrome, 803-805
 - intrapartum, 805-806
 - mild preeclampsia, 795-799
 - postpartum, 806-807
 - severe preeclampsia, 799-803
- pathophysiology, 661-682
- endothelium, 669-671
 - model of, 672
 - normal pregnancy, 662-664
 - preeclampsia, 665-669
 - speculation, 672-673
- prevention of, 779-792
- rationale, 779-780
 - strategies, 780-789
 - nutritional, 780-785
 - pharmacologic, 786-789
- renin-angiotensin-aldosterone system, 683-711
- biochemistry and physiology, 684-689
 - aldosterone, 689
 - angiotensin II, 687-689
 - angiotensin-converting enzyme, 687
 - angiotensinogen, 687

- Preeclampsia (*Continued*)
 first messenger mechanisms, 685-686
 prorenin, 684
 prostaglandins, 686-687
 renin, 684-685
 second and/or third messenger systems, 686
 extrarenal systems, 689-690
 in normal pregnancy, 690-697
 biochemistry and physiology, 691-695
 uteroplacental circulation, 696-697
 pathophysiology, 701-703
 in preeclampsia, 698-700
- Pregnancy, and chemical dependency. See *Chemical dependency and pregnancy*.
 parvovirus B19 infection, 216-219
- Prematurity, and neonatal sepsis, 363-364
- Prenatal, alcohol use in pregnancy, 104-106
 cocaine exposure, developmental defects, 141-144
 injury, tort action, 161-162
 child born alive, 159-160
 wrongful death, 160-161
- Pressures, partial. See *Pulse oximetry*.
- Prophylaxis with immunoglobulins. See *Immunoglobulin prophylaxis and therapy*.
- Prorenin, in normal pregnancy, 691-692
 in renin-angiotensin-aldosterone system, 684
- Prostaglandins, and renin release, 686-687
- Prostanoids and uteroplacental bed, 656-657
- Proteins, brain, cannabis effects, 17
 C and S, 716
- Pulmonary, candidiasis, 269-270
 capillary wedge pressure, 733
 disease, in HIV infection, 233
 edema, in preeclampsia, 737-740
 function, measurement and monitoring, 581-609
 data interpretation, 604-606
 and body weight and growth, 605
 inpatient variability, 605
 lung volume effects, 604-605
 and other aspects of lung function, 605-606
 electrical conductivity, total body, 611-627
 applications, 622-624
 data interpretation, 617-621
 future developments, 624-625
 instrumentation, 615-616
 measurement precision and accuracy, 621-622
 equipment, 582-587
 flow pneumotachometer, 582-585
 hot wire anemometers, 584-585
 pressure measurements, 585-587
 airway, 585
 calibration, 587
 esophageal, 585-587
 tidal volume, 585
 future prospects, 606-607
 mechanics measurements, 587-604
 conventional method, 595-599
 functional residual capacity, 602-604
 occlusion method, 591-595
 multiple occlusions, 591-594
 passive exhalation, 594-595
 regression method, 599-602
 static compliance, 589-591
 injury, treatment with high-frequency ventilation, 573-578
- Pulse oximetry, 441-472
 blood oxygen transport, 441-444
 clinical applications, 457-467
 comparison of SpO_2 with PaO_2 and tcPO_2 , 458-460
 in delivery room, 463-464
 in different gestational ages, 460-462
 limitations in neonates, 465-467
 nursing and medical procedure effects, 462-463
 during surgery and anesthesia, 464-465
 measurement of blood oxygen saturation, 448-453
 normal SpO_2 values, 467-469
 principles of, 453-456
 oximeter calibration and reference instrumentation, 454-455
 technology transition, 445
- Radiant warmers. See *Thermoregulation*.
- Radioisotopes, in PET, 552
- Rash diseases, parvovirus B19, 213-214
- Regression method of pulmonary function measurement, 599-602
- Religion, legal issues, 154
- Renin, in normal pregnancy, 692
 in preeclampsia, 698. See also *Preeclampsia, renin-angiotensin-aldosterone system*.
- Reporting of neonatal addiction, 187
- Resistance. See *Pulmonary function, measurement and monitoring*.
- Respiration, cardiorespiratory monitoring, 474-475
- Respiratory disease, and neonatal mycoplasmal infections, 243-245
- Respiratory system of pregnant substance abuser, 27
- Risk factors, of hypertension in pregnancy, 848-850
 immunoglobulin prophylaxis and therapy, 308-311
 for neonatal sepsis, 362-365
- RNA, brain, cannabis effects, 17

- Screening, automatic, of auditory brainstem response, 505-506
Doppler flow velocimetry, 755-756
for herpes simplex virus infection, 193-196
for HIV infection, 235-236
for neonatal sepsis, 364, 375
SensorMedics 3100 ventilator, 567-568
Sepsis, neonatal, 193-381
candidiasis, 263-280
congenital, 265-275
predisposing factors, 264-265
clinicopathology of diagnosis, 361-381
diagnostic tests, nonspecific, 369-375
laboratory tests, 365-369
management, 375-377
risk factors, 362-365
coagulase-negative staphylococcal infection, 281-302
biology, 282-285
clinical manifestations, 288-291
diagnosis, 291-294
pathogenesis, 285-288
prevention, 296-297
treatment, 294-296
cytokine therapy, 343-359
cytokines, 345-351
myeloid abnormalities, 344-345
and neonatal host defense, 351-355
fibronectin therapy, 325-341
clinical trials, 328-334
immunotherapy in newborn infants, 335-338
structure-function relationships, 326-328
herpes simplex virus infection, 193-208
antenatal screening programs, 193-196
chemotherapy, 202-204
determinants of disease acquisition and severity, 199-202
recognition and diagnosis of, 196-199
human immunodeficiency virus infection, 227-239
clinical manifestation in neonate, 232-233
counseling, 236
epidemiology, 227
laboratory diagnosis, 228-232
management, 236
postnatal acquisition, 233-234
screening policy, 235-236
transmission, 228
treatment, 234-235
immunoglobulin prophylaxis and therapy, 303-323
in congenital and acquired antibody deficiency, 311
intravenous, in neonates, 314-320
intravenous utilization, 305-308
pharmacokinetics, 312-314
risk factors, 308-311
mycoplasmal infections, 241-262
chronic lung disease of newborn, 245-248
CNS infections, 249-252
diagnosis and treatment, 256-259
epidemiology, 242-243
genital mycoplasmas, 254
pathology, 254-256
pneumonia during infancy, 248
respiratory disease, 243-245
parvovirus B19, human, 209-225
epidemiology and natural history, 212
erythema infectiosum (fifth disease) and other B19 rash diseases, 213-214
future needs, 220-221
hematologic complications, 215-216
joint disease, 214-215
laboratory diagnosis, 219-220
in pregnancy, 216-219
virologic background, 210-212
Septicemia, coagulase-negative staphylococcal, 288-289
Skin, artificial. See *Thermoregulation*.
Slime, in coagulase-negative staphylococcal infection, 287-288
Smoke chemistry, of cannabis, 13-15
Social services for pregnancy substance abusers, 30
Spatial resolution, in PET, 551
Species, of coagulase-negative staphylococci, 286-287
Spectroscopy, magnetic resonance. See *Magnetic resonance spectroscopy*.
near-infrared, 519-534
background, 519-522
data instrumentation, 525-527
in future, 532-533
instrumentation, 522-525
neonatal studies, 527-532
Staphylococcal infection, coagulase-negative, 281-302
biology, 292-295
epidemiology, 283-284
identification and classification, 282-283
clinical manifestations, 288-291
endocarditis, 289
meningitis, 289-290
miscellaneous infections, 291
necrotizing enterocolitis, 290
pneumonia, 290-291
septicemia, 288-289
coagulase-negative staphylococcal infection, 281-302
ecology, 284-285
diagnosis, 291-294
pathogenesis, 285-288
bacterial factors, 286-288
delta-like toxin, 288
bacterial factors, 286-288

- Staphylococcal infection (*Continued*)
 slime, 287-288
 species, 286-287
 host factors, 285-286
 routes of infection, 285
 prevention, 296-297
 treatment, 294-296
- State intervention in drug addiction. *See*
Legal issues.
- Static compliance, 589-591
- Stillbirth, and substance abuse, 29
- Streptococcus, group B, maternal, and
 neonatal sepsis, 363
- Structure-function relationships, in
 fibronectin therapy, 326-328
- Surgery, pulse oximetry during, 464-465
- Systemic vascular resistance (SVR), 732
- Technology and the neonate, 389-645
 biomedical technology, 389-401
 future of, 398-400
 risks and pitfalls, 397-398
 use of, 391-397
 cardiorespiratory monitoring, 473-495
 blood gases, 476-477
 documented monitoring, 483-494
 heart rate, 475-476
 obstructive apnea, 477-478
 pneumograms, 478-483
 respiration, 474-475
 electrical conductivity, total body, 611-
 627
 tissue properties and measurement the-
 ory, 612-615
 evoked potential assessment of auditory
 system, 497-518
 auditory brainstem response, 500-506
 case studies, 509-516
 cortical auditory evoked potentials,
 507-509
 electrophysiologic techniques, 498-499
 middle latency responses, 506
 magnetic resonance spectroscopy, 535-
 548
 animal studies, 545
 cerebral hypoxia-ischemia, 540-542
 and cerebral ultrasonography, 543-545
 future, 545-546
 imaging-spectroscopy, 537
 and magnetic resonance imaging, 536
 metabolic studies, 542-543
 normal brain spectrum, 537-540
 phototherapy for neonatal jaundice, 423-
 439
 efficacy of, 424-427
 green light, 427-428
 halogen lamp (metal halide lamp), 428-
 429
 indications, 430-431
 infant well-being during, 434-437
 lamp efficacy, 432-434
 mechanism of action, 429
 termination of, 431-432
 positron emission tomography, 549-562
 principles of, 549-554
 studies in infants, 555-559
 prenatal drug exposure, 629-645
 laboratory tests, 631-636
 maternal interview, 630-631
 specimens used, 636-643
 pulmonary function measurement and
 monitoring, 581-609
 data interpretation, 604-606
 equipment, 582-587
 future of, 606-607
 methods to measure mechanics, 587-
 604
 pulse oximetry, 441-472
 blood oxygen transport, 441-444
 clinical applications, 457-467
 measurements of blood oxygen satura-
 tion, 446-448, 448-453
 normal SpO₂ values, 467-469
 principles of, 453-456
 technology transition, 445
 spectroscopy, near-infrared, 519-534
 background, 519-522
 data interpretation, 525-527
 in future, 532-533
 instrumentation, 522-525
 neonatal studies, 527-532
 thermoregulation, 402-422
 future of, 417-420
 history of, 403-413
 physiology of, 413-417
 ventilation, high-frequency, 563-580
 current ventilators, 564-568
 optimal gas exchange, 568-573
 treatment strategy, 573-578
- Teratogenicity, of alcohol, 99-100
 of aspirin, 788
 of opioids, 54-56
- Thermoregulation, 403-422
 future of, 417-420
 history of, 403-413
 physiology of, 413-417
- Thrombin antithrombin complexes, 714-716
- Thrush, in candidiasis, 268-269
 in HIV infection, 233
- Tidal volume measurement, 585
- Tort and criminal law, 159-164
- Toxicology, of HIV infection, 232
- Toxin, delta-like, 288
- Tracheal aspirates, 368
- Transfusion, and HIV infection, 234
- Transmission of HIV infection, 35-36, 228
 perinatal 39-41
- Trimethaphan, 884

- Ultrasonography, cerebral, and magnetic resonance spectroscopy, 543-545
obstetric, 813-814. See also *Doppler flow velocimetry*.
- Ureaplasma urealyticum. See *Mycoplasma infections*.
- Urinary tract infection, candidiasis, 271
maternal, and neonatal sepsis, 364
- Urine, culture for neonatal sepsis, 367-368
in prenatal drug exposure, 636-637
- Uteroplacental bed, 656-657
Doppler flow velocimetry, 753-754
in preeclampsia, 700
and renin-angiotensin-aldosterone system, 696-697
- Ventilation, high-frequency, **563-580**
current ventilators, 564-568
Bunnell Life Pulse, 564-566
HFV Infant Star, 567
Humming II, 566-567
SensorMedics 3100, 567-568
optimal gas exchange strategies, 568-573
lung inflation, 571-573
oxygenation, 570-571
ventilation, 569
treatment strategies, 573-578
pulmonary injury, 573-578
- Virus. See specific viruses.
- Waveforms. See *Doppler flow velocimetry*.
- Western blot, of HIV infection, 230
- White blood cell count, and neonatal sepsis, 369-372
- Work load of caretakers, and biomedical technology, 394-395
- Wrongful death, 160-161